Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bone BiologicsBBLG +1.86%26 3-Year EBITDA Growth Rate is 81.80% as of Jun. 2026, which is 78% above its 10-year median of 46.00. GuruFocus rates BBLG with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Bone Biologics ranks better than 96.72% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 81.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 62.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 53.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bone Biologics was 81.80% per year. The lowest was 4.60% per year. And the median was 46.00% per year.
Bone Biologics (NAS:BBLG) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bone Biologics 3-Year EBITDA Growth Rate Related Terms
BBLG vs SCNI, ATXI, PTIX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Bone Biologics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bone Biologics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bone Biologics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bone Biologics's 3-Year EBITDA Growth Rate falls into.
Bone Biologics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 81.80% mean?
Bone Biologics (BBLG) has a 3-Year EBITDA Growth Rate of 81.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bone Biologics and its competitors. This is 78% above median its historical median of 46.00. Over the past decade, Bone Biologics' 3-Year EBITDA Growth Rate has ranged from 4.60 to 81.80. According to the industry distribution chart, Bone Biologics ranks #37 out of 1127 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Bone Biologics' 3-Year EBITDA Growth Rate too high?
Bone Biologics' current 3-Year EBITDA Growth Rate of 81.80% is 78% above median its 10-year median of 46.00. Over the past 10 years, this metric has ranged from a low of 4.60 to a high of 81.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Bone Biologics' value of 81.80% is 460.3% above this industry median. Based on the distribution chart, Bone Biologics ranks #37 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bone Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' 3-Year EBITDA Growth Rate compare to SCNI and ATXI?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #37 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Bone Biologics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Bone Biologics' value of 81.80% is 460.3% above this benchmark. Historically, Bone Biologics' own 3-Year EBITDA Growth Rate has ranged from 4.60 to 81.80 over the past decade. While the company's 10-year median is 46.00 vs. the industry median of 14.60, Bone Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current 3-Year EBITDA Growth Rate of 81.80% is 460.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bone Biologics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current 3-Year EBITDA Growth Rate is 81.80%, which is 78% above median its own 10-year median of 46.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current 3-Year EBITDA Growth Rate of 81.80%. The current 3-Year EBITDA Growth Rate is 81.80%, which is 78% above median its 10-year median of 46.00 and 460.3% above the Biotechnology industry median of 14.60. Bone Biologics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bone Biologics (BBLG), the current 3-Year EBITDA Growth Rate is 81.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
26GF Score
Get the complete analysis for BBLG
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBLG has been successfully added to your 
